Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
AVI-5038
print preview
bookmark
share with colleague
General Information
Company
Sarepta Therapeutics Inc.
Description
Neugene antisense oligonucleotide targeting exon 50 of dystrophin gene
Molecular Target
DNA
Mechanism of Action
Latest Stage of Development
Preclinical
Indication
Muscular dystrophy
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information